Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • Data Privacy
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login 
    • Online Member Centre
    • Next Gen Communications Cloud
    • Cision Communications Cloud®
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
Advanced Search
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Canadian Federal Government
      • Canadian Municipal Government
      • Canadian Provincial Government
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

  • Advanced Search
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Hamburger menu
  • Cision Canada
  • Send a Release
  • FR
    • Phone

    • 877-269-7890 from 8 AM - 10 PM ET

    • ALL CONTACT INFO
    • Contact Cision

      877-269-7890
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR

Important Alert on ALYSENA™ 28 and ALYSENA™ 21 with Chipped Pills Français


News provided by

Apotex Inc.

Mar 08, 2018, 13:00 ET

Share this article

Share toX

Share this article

Share toX

TORONTO, March 8, 2018 /CNW/ -

AUDIENCE
Consumers, Physicians, Family Doctors, Gynaecologists, Obstetricians, Pharmacists and Nurses

ALYSENA™ 28 BLISTER (CNW Group/Apotex Inc.)
ALYSENA™ 28 BLISTER (CNW Group/Apotex Inc.)
ALYSENA™ 21 BLISTER (CNW Group/Apotex Inc.)
ALYSENA™ 21 BLISTER (CNW Group/Apotex Inc.)
ALYSENA™ 28 BLISTER (CNW Group/Apotex Inc.) ALYSENA™ 21 BLISTER (CNW Group/Apotex Inc.)

KEY MESSAGES
Apotex Inc. is advising consumers and health care professionals that complaints have been received for packages of ALYSENA™ 28 (21 active pills, and 7 inactive pills that contain no hormones) and ALYSENA™ 21 (21 active pills).

  • Blister packages for ALYSENA™ 28 and ALYSENA™ 21 contain active (pink) pills that may be chipped.

  • Taking pink pills that have a small chip at the edge will not reduce the product's overall effectiveness in preventing pregnancy.

  • Health care professionals are advised to remind consumers to:
    • Check pills before taking them and not consume pills that are chipped or look unusual (including jagged, broken or crumbling);
    • Examine both sides of each pill thoroughly before taking it. It may not be immediately obvious from looking at the blister package that there is a problem with the pills, since the underside of the pill cannot be seen while in the blister pack.
    • If a chipped pill is found, the next unchipped pink pill should be taken. Do not miss a dose.
    • If you have no unchipped pink pills left, then return the package to your pharmacy as soon as possible for a replacement package. Use a non-hormonal method of birth control (such as condoms, spermicidal foam or gel) until a replacement package can be obtained and contact your health care provider for medical advice.
    • Return blister packages containing chipped pills to the pharmacy to get a replacement package. Packages with no chipped pills do not need to be returned.
    • Seek counsel on the proper use of oral contraceptives, and on what to do if you miss a dose as articulated in the patient information leaflet.

WHAT IS THE ISSUE?
Health Canada and Apotex Inc. have received reports for packages of ALYSENA™ 28 and ALYSENA™ 21 where the blister packages contained chipped active (pink) pill.

PRODUCTS AFFECTED

Product

DIN

Strength

Package / Format

ALYSENA™ 28
(Levonorgestrel and Ethinyl
Estradiol Tablets, USP)

02387883

100 mcg / 20 mcg

28 Tablets Blister Pack

Triple Pack

3x28 Tablets Blister Pack

ALYSENA™ 21
(Levonorgestrel and Ethinyl
Estradiol Tablets, USP)

02387875

100 mcg / 20 mcg

 21 Tablets Blister Pack

Triple Pack

3x21 Tablets Blister Pack

BACKGROUND INFORMATION
ALYSENA™ is a prescription medicine used for:
1- Conception control.
2- Treatment of moderate acne vulgaris in women ≥14 years of age who have no known contraindications to oral contraceptive therapy, desire contraception, and have achieved menarche.

This product is manufactured by a 3rd party in Europe for Apotex Inc. During manufacturing, it is possible for pills to chip. However, the overall quality of the intact pills is not affected.

INFORMATION FOR CONSUMERS
ALYSENA™ is a birth control tablet (oral contraceptive) that contains two female sex hormones (levonorgestrel and ethinyl estradiol). Packages of ALYSENA™ 28 should have three rows of pink (active) pills and one row of white inactive (no hormones) pills. Packages of ALYSENA™ 21 should have three rows of pink (active) pills.

Patients are advised to:

  • Check pills before and after taking them out of the blister package.
  • Examine both sides of each pill thoroughly to determine if the pill is chipped. It may not be immediately obvious from looking at the blister package, as the underside of the pill cannot be seen while in the blister package;
    • If a package has a chipped pill, return it to the pharmacy for a replacement package. Packages with no chipped pills do not need to be returned.
    • Do not consume a pill if it's chipped or looks unusual (including jagged, broken or crumbling);
    • Do not miss a dose of the birth control pill.
    • If a chipped pill is found, the next unchipped pink pill should be taken. Do not miss a dose.
    • If you have no unchipped pink pills left, then return the package to your pharmacy as soon as possible for a replacement package. Use a non-hormonal method of birth control (such as condoms, spermicidal foam or gel) until a replacement package can be obtained and contact your health care provider for medical advice.

Patients should not stop taking birth control pills unless advised to do so by their health care provider, as they could get pregnant. Patients should talk to their health care provider if they have questions or concerns about their birth control product, including missed doses and alternatives.

INFORMATION FOR HEALTH CARE PROFESSIONALS
Apotex Inc. advises health care professionals to remind their patients of the following:

  • Check pills before and after taking them out of the blister package.
  • Examine both sides of each pill thoroughly to determine if the pill is chipped. It may not be immediately obvious from looking at the blister package, as the underside of the pill cannot be seen while in the blister package;
    • If a package has a chipped pill, return it to the pharmacy for a replacement package. Packages with no chipped pills do not need to be returned.
    • Do not consume a pill if it's chipped.
    • If a chipped pill is found, the next unchipped pink pill should be taken. Do not miss a dose.
    • If you have no unchipped pink pills left, then return the package to your pharmacy as soon as possible for a replacement package. Use a non-hormonal method of birth control (such as condoms, spermicidal foam or gel) until a replacement package can be obtained and contact your health care provider for medical advice.

  • Do not stop taking birth control pills as this will increase the likelihood of pregnancy. For questions or concerns about birth control products, talk to a health care professional, including about alternatives. Talk to a health care professional if you have any questions or concerns about your birth control product.

  • Read the Consumer Information Leaflet included in the ALYSENA™ packaging for detailed instructions in case of a missed dose.
  • Pharmacists are reminded to:
    • Check each blister pack of ALYSENA™ 21 and ALYSENA™ 28 before dispensing it to make sure the pills look as they should.
    • Report any unusual pills to the company (Apotex Inc) and to Health Canada.

REPORT HEALTH OR SAFETY CONCERNS
Managing marketed health product-related side effects depends on health care professionals and consumers reporting them. Any case of unexpected side effects in patients receiving ALYSENA™28 and ALYSENA™ 21 should be reported to Apotex Inc. or Health Canada.

APOTEX INC. CONTACT INFORMATION
150 Signet Drive
Toronto, ON
M9L 1T9

Telephone: To report a suspected adverse reaction associated with the use of ALYSENA™ 28 and ALYSENA™ 21 (Levonorgestrel and Ethinyl Estradiol tablets, USP 100 mcg/ 20 mcg) patients may contact Apotex Inc. by calling 1-800-667-4708 (select prompt 2), by email at [email protected] or by fax at 1-866-429-9133 or 416-401-3819.

To correct your mailing address or fax number, contact Apotex Inc.

You can report any suspected adverse reactions associated with the use of health products to Health Canada by:

  • Calling toll-free at 1-866-234-2345; or
  • Visiting MedEffect Canada's Web page on Adverse Reaction Reporting (http://www.hc-sc.gc.ca/dhp-mps/medeff/report-declaration/index-eng.php) for information on how to report online, by mail or by fax.

Yours Sincerely,
Original signed by
Colin D'Cunha MBBS,MHSc,FRCPC
Director, Global Medical Affairs
Apotex Inc

SOURCE Apotex Inc.

Related Links

http://www.apotex.ca

Modal title

Organization Profile

Apotex Inc.

    Also from this source

  • Apotex launches nilotinib capsules, the first generic version of Tasigna®(1) in the United States, with 180 days of exclusivity

  • Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact

  • Apotex introduces IVRA™ (Melphalan) hydrochloride injection: First ready to dilute liquid formulation of Melphalan injection approved via 505(b)(2) NDA in the United States

Contact Cision

  • 866-245-2317
    from 8 AM - 10 PM ET
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media

Products

  • Cision Communications Cloud®
  • Media Monitoring
  • Content Distribution
  • Multimedia Distribution
  • Measurement & Analytics
  • Investor Relations

About

  • About Cision Canada
  • About Cision
  • Media Partners
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud®
  • my CNW

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud
  • my CNW
877-269-7890
from 8 AM - 10 PM ET
  • Terms of Use
  • Information Security Policy
  • Site Map
  • Cookie Settings
  • Accessibility Statement
Copyright © 2025 CNW Group Ltd. All Rights Reserved. A Cision company.